• Kai-Yun Mao, Yuan-Chao Cao, Mao-Yan Si, Ding-Yu Rao, Liang Gu, Zhi-Xian Tang, and Shen-Yu Zhu.
• First Clinical Medical College, Gannan Medical University, Ganzhou, China.
• Medicine (Baltimore). 2024 May 3; 103 (18): e37967e37967.

AbstractLung cancer is one of the most prevalent cancers globally, with non-small cell lung cancers constituting the majority. These cancers have a high incidence and mortality rate. In recent years, a growing body of research has demonstrated the intricate link between inflammation and cancer, highlighting that inflammation and cancer are inextricably linked and that inflammation plays a pivotal role in cancer development, progression, and prognosis of cancer. The Systemic Immunoinflammatory Index (SII), comprising neutrophil, lymphocyte, and platelet counts, is a more comprehensive indicator of the host's systemic inflammation and immune status than a single inflammatory index. It is widely used in clinical practice due to its cost-effectiveness, simplicity, noninvasiveness, and ease of acquisition. This paper reviews the impact of SII on the development, progression, and prognosis of non-small cell lung cancer.Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.

13 keywords...

hide…